4.7 Article

Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficile from a Chinese tertiary hospital

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2012.08.011

关键词

Clostridium difficile; Tandem repeat sequence typing (TRST); Antimicrobial susceptibility; Resistance mechanism

资金

  1. Shanghai JiaoTong University School of Medicine Foundation (Shanghai, China)

向作者/读者索取更多资源

Clostridium difficile is a predominant cause of antibiotic-associated diarrhoea. It is increasingly difficult to treat C. difficile infection efficiently owing to its multidrug resistance. In the present study, 60 clinical C. difficile isolates were collected and analysed for their genotype, antimicrobial susceptibility and resistance mechanisms. Tandem repeat sequence typing (TRST) generated 21 types, including the epidemic clone tr017. Antimicrobial susceptibility testing of eight antibiotics was performed by the agar dilution method. Rifampicin, metronidazole and vancomycin remained the most potent agents in vitro, whilst the resistance rates of other agents such as ciprofloxacin, cefoxitin, clindamycin, tetracycline and moxifloxacin varied from 30% to 100%. 73.33% of the strains were multiresistant to at least three classes of antibiotics, and tr017 strains made up the greatest proportion of multidrug resistance. By further investigating the resistance mechanisms, amino acid substitutions in target enzymes encoded by gyrA/gyrB and rpoB were observed in fluoroquinolone-and rifampicin-resistant strains, respectively. The erm(B) gene was the most prevalent in macrolide-lincosamide-streptogramin B (MLSB)-resistant strains, and the ErmB determinant 'Erj2', a novel genetic organisation identified in this study, plays a central role in conferring resistance, especially in epidemic strains. Moreover, transposon Tn916 carrying the tet(M) gene is more common than Tn5397 in tetracycline resistance. (C) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
Review Infectious Diseases

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman

Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)

Article Infectious Diseases

Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri

Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)